Moderna (NASDAQ:MRNA) Announces Earnings Results

Moderna (NASDAQ:MRNA) posted its quarterly earnings data on Thursday. The company reported ($3.07) EPS for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52, Briefing.com reports. The company had revenue of $167.00 million for the quarter, compared to analyst estimates of $93.26 million. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The business’s revenue was down 91.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.19 earnings per share.

Moderna Trading Down 0.5 %

NASDAQ MRNA traded down $0.59 on Friday, reaching $125.00. The company had a trading volume of 4,512,362 shares, compared to its average volume of 4,144,759. The stock’s 50 day moving average is $105.05 and its 200-day moving average is $94.37. The stock has a market cap of $47.86 billion, a price-to-earnings ratio of -10.07 and a beta of 1.57. The company has a quick ratio of 3.36, a current ratio of 3.42 and a debt-to-equity ratio of 0.04. Moderna has a 52 week low of $62.55 and a 52 week high of $142.79.

Insider Activity at Moderna

In related news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $108.54, for a total value of $1,628,100.00. Following the completion of the sale, the director now owns 2,131,931 shares in the company, valued at $231,399,790.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $108.54, for a total value of $1,628,100.00. Following the completion of the sale, the director now directly owns 2,131,931 shares in the company, valued at $231,399,790.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO James M. Mock sold 705 shares of the stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $101.93, for a total value of $71,860.65. Following the completion of the sale, the chief financial officer now owns 5,048 shares of the company’s stock, valued at $514,542.64. The disclosure for this sale can be found here. Over the last quarter, insiders sold 139,954 shares of company stock worth $14,822,576. 15.70% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms have commented on MRNA. Oppenheimer boosted their price objective on Moderna from $142.00 to $163.00 and gave the stock an “outperform” rating in a research note on Friday. William Blair restated a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. Jefferies Financial Group restated a “buy” rating and set a $125.00 target price on shares of Moderna in a research report on Tuesday, April 9th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research report on Thursday. Finally, Canaccord Genuity Group boosted their target price on Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a research report on Friday. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $129.55.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.